Cisapride-Induced Torsades de Pointes
JOÃO VITOLA M.D., JASMINKA VUKANOVIC M.D.,
DAN M. RODEN M.D.,
JASMINKA VUKANOVIC M.D.
Vanderbilt University School of Medicine, Departments of Medicine and Pharmacology, Nashville, Tennessee
Contributed equally to the final manuscript.
Search for more papers by this authorCorresponding Author
DAN M. RODEN M.D.
Vanderbilt University School of Medicine, Departments of Medicine and Pharmacology, Nashville, Tennessee
Dan M. Roden, M.D., Director, Division of Clinical Pharmacology. Vanderbilt University School of Medicine, 532 Medical Research Building-I, Nashville, TN 37232-6602. Fax: 615-343-4522; E-mail: [email protected]Search for more papers by this authorJOÃO VITOLA M.D., JASMINKA VUKANOVIC M.D.,
DAN M. RODEN M.D.,
JASMINKA VUKANOVIC M.D.
Vanderbilt University School of Medicine, Departments of Medicine and Pharmacology, Nashville, Tennessee
Contributed equally to the final manuscript.
Search for more papers by this authorCorresponding Author
DAN M. RODEN M.D.
Vanderbilt University School of Medicine, Departments of Medicine and Pharmacology, Nashville, Tennessee
Dan M. Roden, M.D., Director, Division of Clinical Pharmacology. Vanderbilt University School of Medicine, 532 Medical Research Building-I, Nashville, TN 37232-6602. Fax: 615-343-4522; E-mail: [email protected]Search for more papers by this authorAbstract
Cisapride-Induced Torsades de Pointes. Two cases of torsades de pointes associated with cisapride are presented, both in association with concomitant drug therapy that inhibits cisapride biotransformation. In one case, plasma cisapride was elevated days after the event, strongly supporting a role for accumulation of the drug in causing the arrhythmia. It is emphasized that these adverse drug reactions are not idiosyncratic, hut rather are predictable based on an understanding of the underlying mechanisms.
References
- 1 Tan HL, Hou CJ, Latier MR, et al: Electrophysiologic mechanisms of the long QT interval syndromes and torsade de pointes. Ann Intern Med 1995; 122: 701–714.
- 2 Roden DM: Current status of class III antiarrhythmic therapy. Am J Cardiol 1993; 72: 44B–49B.
- 3 Annese V, Lombardi G, Frusciante V, et al: Cisapride and erythromycin prokinetic effects in gastroparesis due to type 1 (insulin-dependent) diabetes mellitus. Aliment Pharmacol Ther 1997; 11: 599–603.
- 4 Sjogren RW: Gastrointestinal features of scleroderma. Curr Opin Rheumatol 1996; 8: 569–575.
- 5 Minami T, Nishibayashi H, Shinomura Y, et al: Effects of erythromycin in chronic idiopathic intestinal pseudo-obstruction. J Gastroenterol 1996; 31: 855–859.
- 6 Camilleri M: Gastrointestinal problems in diabetes. Endocrinol Metab Clin North Am 1996; 25: 361–378.
- 7 Mearin F, Malagelada JR: Gastroparesis and dyspepsia in patients with diabetes mellitus. (Review) Eur J Gastroenterol Hepatol 1995; 7: 717–723.
- 8 Olsson S, Edwards IR: Tachycardia during cisapride treatment. Br Med J 1992; 305: 748–749.
- 9 Bran S, Murray WA, Hirsch IB, et al: Long QT syndrome during high-dose cisapride. Arch Intern Med 1995; 155: 765–768.
- 10 Lewin MB, Bryant RM, Fenrich AL, et al: Cisapride-induced long QT interval. J Pediatr 1996; 128: 279–281.
- 11 Klausner MA, and Janssen Pharmaceutical Research Foundation. Dear Doctor Letter.
- 12 Wysowski DK, Bacsanyi J: Cisapride and fatal arrhythmia. N Engl J Med 1996; 335: 290–291.
- 13 Bedford TA, Rowbotham DJ: Cisapride—Drug interactions of clinical significance. Drug Saf 1996; 15: 167–175.
- 14 Woosley RL, Chen Y, Freiman JP, et al: Mechanism of the cardiotoxic actions of terfenadine. JAMA 1993; 269: 1532–1536.
- 15 Crumb WJ Jr, Wible B, Arnold DJ, et al: Blockade of multiple human cardiac potassium currents by the antihistamine terfenadine: Possible mechanism for terfenadine-associated cardiotoxicity. Mol Pharmacol 1995; 47: 181–190.
- 16 Rampe D, Wible B, Brown AM, et al: Effects of terfenadine and its metabolites on a delayed rectifier K+ channel cloned from human heart. Mol Pharmacol 1993; 44: 1240–1245.
- 17 Yang T, Prakash C, Roden DM, et al: Mechanism of block of a human cardiac potassium channel by terfenadine racemate and enantiomers. Br J Pharmacol 1995; 115: 267–274.
- 18 Roy ML, Dumaine R, Brown AM: HERG, a primary human ventricular target of the nonsedating antihistamine terfenadine. Circulation 1996; 94: 817–823.
- 19 Honig PK, Woosley RL, Zamani K, et al: Changes in the pharmacokinetics and electrocardiographic pharmacodynamics of terfenadine with concomitant administration of erythromycin. Clin Pharmacol Ther 1992; 52: 231–238.
- 20 Honig PK, Wortham DC, Zamani K, et al: Terfenadine-ketoconazole interaction. Pharmacokinetic and electrocardiographic consequences. JAMA 1993; 269: 1513–1518.
- 21 Zimmemiann M, Duruz H, Guinand O, et al: Torsades de pointes after treatment with terfenadine and ketoconazole. Eur Heart J 1992; 13: 1002–1003.
- 22 Monahan BP, Ferguson CL, Killeavy ES, et al: Torsades de pointes occurring in association with terfenadine use. JAMA 1990; 264: 2788–2790.
- 23
Honig PK,
Wortham DC,
Hull R, et al: Itraconazole affects single-dose terfenadine pharmacokinetics and cardiac repolarization pharmacodynamics.
J Clin Pharmacol
1993; 33: 1211–1206.
10.1002/j.1552-4604.1993.tb03920.x Google Scholar
- 24 Benton RE, Honig PK, Zamani K, et al: Grapefruit juice alters terfenadine pharmacokinetics, resulting in prolongation of repolarization on the electrocardiogram. Clin Pharmacol Ther 1996; 59: 383–388.
- 25 Corinaldesi R, Stanghellini V, Tosetti C, et al: The effect of different dosage schedules of cisapride on gastric emptying in idiopathic gastroparesis. Eur J Clin Pharmacol 1993; 44: 429–432.
- 26 Carlsson L, Amos GJ, Andersson B, et al: Electrophysiological characterization of the prokinetic agents cisapride and mosapride in vivo and in vitro—Implications for proarrhythmic potential. J Pharmacol Exp Ther 1997; 282: 220–227.
- 27 Puisieux FL, Adamantidis MM, Dumotier BM, et al: Cisapride-induced prolongation of cardiac action potential and early afterdepolarizations in rabbit Purkinje fibres. Br J Pharmacol 1996; 117: 1377–1379.
- 28 Lopez JA, Harold JG, Rosenthal MG, et al: QT prolongation and Torsades de Pointes after administration of trimethoprim-sulfametroxazole. Am J Cardiol 1987; 59: 376–377.
- 29 Roden DM, Lazzara R, Rosen MR, et al, and the SADS Foundation Task Force on LQTS: Multiple mechanisms in the long QT syndrome: Current knowledge, gaps, and future directions. Circulation 1996; 94: 1996–2012.
- 30 Makkar RR, Fromm BS, Steinman RT, et al: Female gender as a risk factor for torsades de pointes associated with cardiovascular drugs. JAMA 1993; 270: 2590–2597.
- 31 Nattel S, Ranger S, Talajic M, et al: Erylhromycin-induced long QT syndrome: Concordance with quinidine and underlying cellular electrophysiologic mechanism. Am J Med 1990; 89: 235–238.
- 32 Rubart M, Pressler ML, Pride HP, et al: Electrophysiological mechanisms in a canine model of erythromycin-associated long QT syndrome. Circulation 1993; 88: 1832–1844.
- 33 McComb JM, Campbell NPS, Cleland J: Recurrent ventricular tachycardia associated with QT prolongation after mitral valve replacement and its association with intravenous administration of erythromycin. Am J Cardiol 1984; 54: 922–923.
- 34 Sanguinetti MC, Jiang C, Curran ME, et al: A mechanistic link between an inherited and an acquired cardiac arrhythmia: HERG encodes the IKr potassium channel. Cell 1995; 81: 299–307.
- 35 Napolitano C, Priori SG, Schwartz PJ, et al: Identification of a long QT syndrome molecular defect in drug induced torsades de pointes. (Abstract) Circulation 1997; 96: I–211.
- 36 Schultz-Bahr E, Haverkamp W, Hordt M, et al: Do mutations in cardiac ion channel genes predispose to drug-induced (acquired) long QT syndrome? (Abstract) Circulation 1997; 96: 1–211.
- 37 Eichelbaum M, Gross AS: The genetic polymorphism of debrisoquine/sparteine metabolism—Clinical aspects. Pharmacol Ther 1990; 46: 377–394.
- 38 Mörike KE, Roden DM: Quinidine-enhanced beta blockade during treatment with propafenone in extensive metabolizer human subjects. Clin Pharmacol Ther 1994; 55: 28–34.
- 39 Edeki TI, He H, Wood AJ: Pharmacogenetic explanation for excessive beta-blockade following timolol eye drops. Potential for oral-ophthalmic drug interaction. JAMA 1995; 274: 1611–1613.
Citing Literature
